CLINICAL TRIAL SUMMARY

MDACC Study No:2013-0012 (clinicaltrials.gov NCT No: NCT01895842)
Title:PHASE I STUDY OF RUXOLITINIB FOR PATIENTS WITH LOW OR INTERMEDIATE-1 RISK MYELODYSPLASTIC SYNDROME
Principal Investigator:Guillermo Garcia-Manero
Treatment Agent:Ruxolitinib
Study Status:Open
Study Description:The goal of this clinical research study is to find the highest tolerable dose
of ruxolitinib that can be given to patients with low or intermediate-1 risk
MDS. The safety of this drug will also be studied, and whether it can help to
control the disease.

Hide details for General InformationGeneral Information

Disease Group:Leukemia
Phase of Study:Phase I
Treatment Agents:Ruxolitinib
Treatment Location:Only at MDACC
Estimated Length of Stay in Houston:
Supported By:Incyte
Return Visit:
Home Care:


Hide details for Study Contact InformationStudy Contact Information

Physician Name:Guillermo Garcia-Manero
Dept:Leukemia
For Clinical Trial Enrollment:713-745-3428
For General Questions about Clinical Trials:1-877-MDA-6789


Show details for Study Objectives / OutcomesStudy Objectives / Outcomes
Show details for Study Status InformationStudy Status Information
Show details for Enrollment EligibilityEnrollment Eligibility
Show details for Resources and LinksResources and Links
Show details for ResultsResults